ArticleFrontiers in pediatrics2026
Single-center experience of interventional therapy for congenital portal-systemic shunt in children.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the safety and short-term efficacy of interventional therapy for congenital portosystemic shunt (CPSS) in children, and to provide single-center small-sample empirical data for clinical practice. Methods: A retrospective analysis was conducted on the clinical data of 26 children with CPSS who underwent interventional therapy at Capital Center for Children's Health, Capital Medical University from January 2022 to August 2025. Based on anatomical subtypes, they were categorized into the intrahepatic portal-systemic shunt group (18 cases) and the Abernethy malformation group (8 cases). Techniques such as coil embolization and Amplatzer occluder embolization were employed. Postoperative follow-up was performed for 1-12 months to evaluate technical success rates, complication rates, and improvements in liver function and blood ammonia levels. Results: The success rate of interventional therapy in 26 pediatric patients was 73% (19/26). Among them, the technical success rate in the intrahepatic portal-systemic shunt group was 94.4% (17/18), while the Abernethy malformation technique achieved a success rate of 25% (2/8). The incidence of mild complications within 1 month postoperatively was 3.8% (1/26), including 1 case of puncture site hematoma, with no severe complications reported. Among the successfully treated patients, the normalization rate of postoperative liver function parameters [Alanine aminotransferase (ALT), Aspartate aminotransferase (AST)] was 63% (12/19), the improvement rate of bile acids was 73.7% (14/19), and the improvement rate of blood ammonia was 100% (19/19). Conclusion: The individualized interventional embolization strategy for children with different anatomical subtypes of CPSS is safe and effective, with definite short-term efficacy, and can be used as the first-line treatment for CPSS children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.